SCHEMBL2807655

SCHEMBL2807655

O=C(CCNC(=O)OCc1ccccc1)Nc1cc(-c2ccccc2)ccc1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TPSAB1 Q15661 4/20 0.46
TPSD1 Q9BZJ3 4/20 0.46
TPSG1 Q9NRR2 4/20 0.46
ELANE P08246 2/20 0.46
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 1/20 0.44
MGLL Q99685 3/20 0.43
PLG P00747 1/20 0.42
HTT P42858 1/20 0.42
KAT2B Q92831 1/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ENPP2 Q13822 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2567924 0.84 MGLL (0.54) MEN1KMT2AL3MBTL1TPSAB1TPSD1
SCHEMBL2574008 0.76 HDAC3 (0.47) TPSAB1TPSD1TPSG1ELANEHDAC1
SCHEMBL8861893 0.72 HTT (0.54) TPSAB1TPSD1TPSG1ELANEPRSS1
SCHEMBL2573590 0.71 MGLL (0.63) MEN1KMT2AL3MBTL1HDAC1HDAC2
SCHEMBL6387882 0.71 HTT (0.57) MEN1KMT2AL3MBTL1TPSAB1PRSS1
SCHEMBL2804971 0.71 MGLL (0.62) MEN1KMT2AL3MBTL1HDAC1HDAC2
SCHEMBL5191097 0.71 KMT2A (0.60) MEN1KMT2AL3MBTL1HTTLMNA
SCHEMBL2570879 0.70 CASP3 (0.44) KMT2A
SCHEMBL11847025 0.69 ALDH1A1 (0.47) MEN1KMT2AL3MBTL1HDAC1HDAC2
SCHEMBL1206224 0.68 ACHE (0.55) TPSAB1TPSD1TPSG1ELANEPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249054-A9 PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 US disclosed
US-7795236-B2 Purine nucleoside derivative modified in 8-position and medical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-09-14 US disclosed
US-20070179115-A1 Purinenucleoside derivative modified in 8-position and medical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249054-A9 PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF NUDT1, PNP, SLC28A2 MEN1 3310/4885KMT2A 2172/4885L3MBTL1 483/4885
US-20070179115-A1 Purinenucleoside derivative modified in 8-position and medical use thereof NUDT1, SLC28A2, PNP MEN1 3540/4885KMT2A 1816/4885L3MBTL1 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.